Filing Details
- Accession Number:
- 0001438133-20-000017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-24 16:35:02
- Reporting Period:
- 2020-02-21
- Accepted Time:
- 2020-02-24 16:35:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438133 | Tandem Diabetes Care Inc | TNDM | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365369 | F John Sheridan | C/O Tandem Diabetes Care, Inc. 11075 Roselle Street San Diego CA 92121 | President & Ceo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-02-21 | 30,000 | $2.59 | 32,501 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-21 | 16,458 | $87.39 | 16,043 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-21 | 12,842 | $88.38 | 3,201 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-21 | 700 | $89.62 | 2,501 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2020-02-21 | 30,000 | $0.00 | 30,000 | $2.59 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,667 | No | 4 | M | Direct |
Footnotes
- Represents shares of common stock received upon exercise of a stock option award.
- The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2019, as amended on December 16, 2019.
- The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $87.00 to $87.97. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $88.01 to $88.90. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $89.60 to $89.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- The option shall vest as to fifty percent (50%) of the underlying shares on 12/01/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter.
- The expiration date for these options is 10 years from the date of grant.
Billionaire Hedge Funds
